Evidence map›Paper›PMID 41393243›Full record

Trial reportPrecision clinical medicine2025

Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms.

Anzhu Wang, Yishan Huang, Yu Wei, Lili Zhang, Hongdong Chen, Xiaoqing Wang, Zhimei Cui, Bin Wang, Wei Liu, Chao Chen and 8 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Precision clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anzhu WangKey Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Yishan HuangMetabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Yu WeiMetabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Lili ZhangMetabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Hongdong ChenDepartment of Endocrinology, Beijng Hepingli Hospital, Beijing 100013, China.
Xiaoqing WangBaoding Traditional Chinese Medicine Hospital, Baoding 071000, China.
Zhimei CuiShijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang 050051, China.
Bin WangZouping Country Hospital of Traditional Chinese Medicine, Zouping 256200, China.
Wei LiuThe Central Hospital of Yongzhou, Yongzhou 425006, China.
Chao ChenShantou Traditional Chinese Medicine Hospital, Shantou 515031, China.
Ye LeiThe Second Affiliated Hospital of Shaanxi University of Traditional Chinese medicine, Xianyang 712000, China.
Zhonghua ZhengZhengzhou Traditional Chinese Medicine Hospital, Zhengzhou 450007, China.
Yan WeiHangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, China.
Jia MiAffiliated Hospital of Changchun University of Chinese Medicine, Changchun 130021, China.
Keda LuZhejiang Provincial Hospital of Chinese Medicine, Hangzhou 310005, China.
Ying ZhangBeijing University of Chinese Medicine, Beijing 100029, China.
Xiaolin TongMetabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Linhua ZhaoMetabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Shenzhuo Formula (SZF), a modified Didang Tang, is used for diabetic kidney disease (DKD), though high-quality evidence is limited. Methods: In a randomized, double-blind, double-dummy, active-controlled, multicenter trial, irbesartan (IRB) was the control. A Bayesian model assessed efficacy. Mechanistic studies included Olink inflammation proteomics, single-cell RNA sequencing (scRNA-seq) of KK-Ay mouse kidneys, and Results: A total of 120 DKD patients with macroalbuminuria were randomized (SZF Conclusions: SZF matched IRB in proteinuria reduction but was superior in preserving renal function and improving traditional Chinese medicine symptoms in DKD, with good safety. Benefits may involve suppression of CX3CL1/MCP-1-mediated inflammation.

Indexed as

diabetic kidney diseasemacroalbuminuriaShenzhuo Formulatraditional Chinese medicine

Identifiers

PMID41393243
PMCPMC12699223

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.